Pfizer Reports Sutent Safe And Effective In Asians; Forges Alliances With Major Asian Oncology Centers
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Pfizer Sept. 21 released data on a Phase IIIb Asian trial of its leading oncology drug multi-kinase inhibitor Sutent, which demonstrated similar effectiveness and tolerability in Asians as in non-Asians